Breaking AI & Tech News Analyzed

Scientists at London's Institute of Cancer Research and the RCSI University of Medicine and Health Sciences in Dublin have announced a new AI-driven approach to identify how patients with advanced bowel cancer will respond to bevacizumab, a drug recently introduced by the NHS. The method uses PhenMap, an AI tool that integrates complex data on the genetic makeup of tumors, allowing researchers to track patterns of how different patients react to the drug. This development aims to spare potentially thousands of patients from being given drugs that would be ineffective in fighting their cancers. In the UK alone, nearly 10,000 cases of advanced bowel cancer are identified every year, with young adults seeing a particular rise in diagnoses. Bowel cancer has the second-highest mortality rate of any cancer, behind only lung cancer. While survival rates can be as high as 98% when caught early, the five-year survival rate for advanced bowel cancer can be as low as 10%. The study tracked 117 European bowel cancer patients who had been treated with chemotherapy and bevacizumab. Researchers identified a group of patients who all had the same gene mutation and were at a high risk of having negative reactions. The scientists behind the tests now hope to expand the number of patient samples and see if the results can be used in treatments for other types of cancer. Anguraj Sadanandam, a professor in stratification and precision medicine at the ICR, said: “Once bowel cancer spreads to other parts of the body, there are very few treatment options available for patients. It is therefore positive that patients can now access the targeted drug bevacizumab on the NHS. However, we know that the majority of patients won’t benefit from the drug, meaning thousands of people in England could be facing unpleasant side effects unnecessarily.” Sadanandam added that while the findings were encouraging, the tool would need to be tested on a larger cohort to be validated. “In future, I hope this approach will lead to a test that can be used by clinicians, to ensure patients receive personalised care that has the highest chance of working against their cancer.”

GSK has revealed promising early results for its treatment for gynaecological cancers, Mocertatug Rezetecan (Mo-Rez), as its chief executive, Luke Miels, seeks to speed up drug development at the group.The company reported that in an early-stage trial, Mo-Rez shrank or eliminated tumours in 62% of patients with ovarian cancer where chemotherapy had failed, and in 67% of those with endometrial cancer.GSK acquired the Mo-Rez cancer treatment, an antibody-drug conjugate (ADC), from China’s Hansoh Pharma in late 2023, and has trialled it in 224 patients around the world, including the UK, over the past year. Few patients needed to stop treatment because of side-effects, the most common being nausea. It is administered every three weeks via intravenous infusion.Combined with data from a separate, intermediate trial in China, these results give GSK the confidence to go straight to late-stage trials, with five clinical studies planned globally in the next few months, including on patients in the UK.Presenting the results at the Society of Gynecologic Oncology’s annual meeting on women’s cancer in Puerto Rico, Hesham Abdullah, GSK’s global head of cancer research and development, said: “Treatment of gynaecological cancers remains a major challenge, with a pressing need for new therapies that offer improved response rates. With Mo-Rez we now have compelling evidence of a promising clinical profile.”Endometrial cancer affects 1.6 million women globally, with 417,000 new cases each year. Ovarian cancer affects 843,000 people, with 240,000 new cases annually.Abdullah described Mo-Rez as a “key asset” in the company’s growing cancer portfolio, expected to be a blockbuster drug with peak annual sales of more than £2bn, which GSK hopes will help it achieve its 2031 sales target of £40bn.

The play 'My Uncle Is Not Pablo Escobar' showcases creative ambition in its exploration of the experiences of Latinx women in modern London. The production features striking visuals, blending elements of a pop concert with techno beats and census data, highlighting the absence of Latinx representation in official categories.The narrative takes a fictional turn, loosely inspired by the 2012 HSBC scandal, centering on Ale, a young woman juggling her A-levels with shifts as a bank cleaner, and her investigative journalist sister Cata. Together, they recruit Lucia to go undercover and investigate the bank's exploitative practices.Despite inventive uses of props and moments of tension, the play feels like a mesh of ideas rather than a fluid narrative. The involvement of five writers and occasional voiceovers may contribute to this disjointedness. The play touches on themes of sibling tension, identity crisis, and immigration, but these elements seem somewhat disconnected.The production at Brixton House in London until May 3rd, serves as a reminder of the importance of Latinx stories on stage, particularly given the growing Latinx population in the UK. However, 'My Uncle Is Not Pablo Escobar' ultimately lacks a unifying focus, causing its message to get lost in the narrative.

Malina Lee, a 31‑year‑old wedding baker from San Antonio, joined TikTok in 2020 to pass the lockdown‑induced boredom and promote her business. Four years later, an anonymous commenter called “PickleFart” noticed an asymmetrical neck in one of her videos and suggested she check for a goiter.The tip proved accurate: doctors confirmed thyroid cancer. Lee received prompt treatment and, within a year, was declared cancer‑free. She told the outlet that her oncologist was amazed at how early the disease was caught, crediting the TikTok comment as the catalyst.Lee’s experience is part of a growing trend where TikTok’s hyper‑targeted algorithm surfaces health‑related content that resonates with users’ unnoticed symptoms. In several cases, community members have flagged potential conditions that clinicians initially missed.The “PickleFart” persona belongs to Billie Jean Tuomi, who calls herself the “thyroid avenger.” A thyroid‑cancer survivor herself (diagnosed in 2012), Tuomi now scans videos for neck asymmetry and gently advises creators to seek a thyroid panel—a blood test measuring hormone levels and antibodies. The American Thyroid Association recommends adults start routine thyroid testing at age 35, or annually for high‑risk individuals.Tuomi estimates she has flagged dozens of videos, with at least four confirmed serious thyroid issues, including Lee’s. She stresses she does not claim to diagnose, merely urges viewers to consult a physician. After a viral comment, she received a flood of private messages with neck photos, prompting her to change her username.Lee, inspired by Tuomi’s intervention, has begun commenting on other users’ videos, helping one individual discover an enlarged thyroid that required removal. She describes the process as a “domino effect” of community‑driven health awareness.Medical professionals acknowledge the double‑edged nature of this phenomenon. Craig Mittleman, director of emergency services at Lawrence + Memorial Hospital, notes a rise in patients arriving with self‑diagnoses sourced from social media. While this can empower patients to ask informed questions, it also burdens clinicians with debunking misinformation.Gender disparities amplify the issue: research shows women are more likely to seek health information online, often after feeling dismissed by traditional providers. TikTok user Tori Mosser, a 23‑year‑old filmmaker, credits a direct message suggesting chronic appendicitis for prompting surgery that resolved her chronic vomiting episodes.Both Lee and Mosser emphasize the therapeutic value of finding a supportive community on TikTok, especially for invisible or chronic illnesses that are frequently minimized in clinical settings.

OpenAI, a leading AI company, has recently released a 13-page policy paper titled 'Industrial Policy for the Intelligence Age,' which calls for a reimagining of the social contract around 'a slate of people-first ideas.' This move is part of an aggressive effort by major AI players to reshape the narrative around their industry, as public disapproval of AI is increasing.OpenAI's paper proposes ideas such as a four-day workweek and a public wealth fund that would return profits directly to citizens. While the company presents these ideas as a starting point for a broader conversation, critics argue that they are more of a public relations ploy than a genuine policy document.OpenAI spent nearly $3m on lobbying in 2025, and its president, Greg Brockman, co-founded a pro-AI Super Pac that raised more than $125m last year. The company is also backing a bill in Illinois that would shield AI firms from liability in cases where an AI model causes serious societal harms.Critics argue that these efforts are aimed at undermining independent efforts to regulate the industry and that the company's proposals shift responsibility away from the company and towards the public and lawmakers. As public distrust of AI grows, the industry is looking for ways to reframe the debate and influence regulation.A Pew Research Center survey found that only 16% of Americans believe that AI will help people think more creatively, while only 5% of Americans believe it will help people better form meaningful relationships. An NBC News poll found that only 26% of voters had a favorable opinion of AI, with a net negative rating.

The latest analysis by HR consultancy Hamilton Nash shows that 54 employment tribunals in England, Scotland and Wales cited remote‑working issues in 2025 – a 13% decline from the previous year and the first drop since the pandemic began.This marks the end of a six‑year upward trend during which tribunal filings related to remote work surged tenfold from the pre‑COVID baseline of 2019. The number of cases peaked at 62 in 2024 but fell sharply to just six in 2025.According to the Office for National Statistics, 28% of working‑age adults in Great Britain now operate in a hybrid model, splitting time between a traditional office and another location such as home. Yet many large employers, notably financial giants Goldman Sachs and JPMorgan Chase, have intensified return‑to‑office mandates, with some demanding five days a week on site.Employment experts attribute the unexpected dip to broader labour‑market dynamics. The UK unemployment rate rose to a near five‑year high of 5.2% in Q4 2025, while job vacancies have continued to fall, shifting bargaining power back toward employers. As Jim Moore, employee‑relations partner at Hamilton Nash, explains, “Top talent did vote with their feet for a while, but that has changed because of wider issues in the labour market and people saying: ‘I am going to stay put and keep my head down.’”Legislative changes may also be curbing tribunal filings. The amended Employment Relations Act, which introduced a right to request flexible working from day one of a new job in April 2024, appears to encourage employees to resolve disputes internally rather than through the courts.Moore warns that tribunal numbers represent “the tip of the iceberg,” noting that much workplace conflict never reaches a public hearing. Adding to employer confidence, a 2024 tribunal decision rejected a senior manager’s claim against the Financial Conduct Authority for the right to work entirely from home, a ruling that, according to Hill Dickinson partner Padma Tadi‑Booth, “may give some encouragement to employers” to tighten office‑attendance policies.Consequently, some firms are already planning to raise on‑site requirements, moving from two to three days a week or mandating a higher percentage of total working hours in the office.Nevertheless, the backlog of employment tribunals remains a significant hurdle. Over 500,000 cases were pending last year, and claimants can expect waits of up to three years for a hearing, potentially deterring future filings.

Music lovers and Beatles fans are in for a treat tonight as McCartney: The Hunt for the Lost Bass airs on BBC Two at 8:45pm. This documentary delves into the mysterious disappearance of Paul McCartney's iconic Höfner bass guitar, which he purchased in 1961 during the formative years of the Beatles. The instrument, which became synonymous with McCartney's music, vanished around the time of the Beatles' split and has been on a journey of its own ever since. The documentary features contributions from 'bass detectives' and McCartney himself, offering a fresh perspective on a well-known story. In other TV news, Proper Ladies on BBC Three at 7:45pm showcases new talent with a comedy short film initiative, beginning with Sabrina Ali's play Dugsi Dayz, a coming-of-age story about four Muslim girls. Celebrity Sabotage on ITV1 at 8pm features civilians competing in a military endurance series, while celebrities and a guest saboteur try to disrupt the proceedings from a nearby bunker. Film enthusiasts can look forward to Outcome on Apple TV, a comedy starring Keanu Reeves as Reef Hawk, a celebrated actor and secret recovering heroin addict. The movie follows his apology tour to find the culprit behind a compromising video. Sporting events include Premier League football matches, the Grand National Festival, Women's Six Nations Rugby Union, and a boxing match between Tyson Fury and Arslanbek Makhmudov.

Ukrainian President Volodymyr Zelenskyy has confirmed that his country's technology played a crucial role in shooting down Iranian drones in the Middle East. This development comes after Zelenskyy announced last month that expert teams had been deployed to the region following the outbreak of the United States-Israeli war on Iran.In a recent statement, Zelenskyy revealed that Ukrainian forces participated in operations using domestically produced interceptor drones against 'Shahed' drones, which are similar to those used by Russia during its ongoing conflict with Ukraine.Key highlights of Zelenskyy's statement include:Ukrainian forces successfully destroyed Iranian 'shaheds' in several countries.The operations were not limited to training missions but involved actual support in building modern air defence systems.Ukrainian experts provided crucial advice on strengthening air defence systems in countries that collaborated with them.Zelenskyy expressed optimism about the future, stating that it is only a matter of time before mass production of interceptors capable of destroying drones with jet engines commences.Kyiv has effectively utilized cheap drone interceptors to neutralize Russian drones before they reach their targets. As part of the agreement, Ukraine is receiving weapons to protect its energy infrastructure and, in some cases, financial arrangements.During his recent visits to Gulf nations, including Qatar, Saudi Arabia, Jordan, and the United Arab Emirates, Zelenskyy signed defence agreements with the UAE, Qatar, and Saudi Arabia.

In an era where pop stardom is measured by a patchwork of streaming figures, award nods and high‑profile support slots, Holly Humberstone has built a credible résumé without ever cracking the singles chart. The 26‑year‑old from Lincolnshire has leveraged a Brit Rising Star award, a coveted opening for Taylor Swift, and four million monthly Spotify listeners to cement her place in the contemporary pop landscape.Her second album, ‘Cruel World’, marks a decisive shift from the gothic melancholy that defined her debut, Paint My Bedroom Black. The new record embraces an 80s‑inspired synth‑pop palette brimming with ear‑catching hooks, delivering lyrics that are both earnest and conversational, reminiscent of Swift’s confessional style.Highlights include the sun‑soaked breakup anthem ‘To Love Somebody’, which builds to a stadium‑ready pre‑chorus, and the irresistibly catchy ‘White Noise’, a nostalgic nod to disco that channels the energy of early‑2000s Kylie Minogue. Even the cheeky, self‑aware line on “Drunk Dialling” – “I’m gonna shake my nonexistent ass to this shitty song” – showcases Humberstone’s willingness to blend humor with polished production.The album’s production is consistently confident, featuring a surprising happy‑hardcore breakdown on the closing track “Make It All Better.” Combined with Humberstone’s knack for crafting crowd‑pleasing melodies, these elements suggest she is poised for a long‑term pop career that can thrive in both traditional and modern market models.